AstraZeneca plc stock (GB0009895292): Global pharma leader with strong oncology pipeline

AstraZeneca plc, a leading biopharmaceutical company, maintains its position as a global innovator in oncology, rare diseases, and bioelectronics. Recent developments underscore its robust pipeline, including advancements in antibody-drug conjugates and next-generation therapies. US investors track the stock for its exposure to high-growth areas amid evolving healthcare demands.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

AstraZeneca plc: core business model

AstraZeneca plc focuses on developing and commercializing prescription medicines across three core therapy areas: Oncology, Rare Diseases, and BioPharmaceuticals. The company invests heavily in research and development, with a pipeline exceeding 180 projects as of its latest annual report published in February 2025 covering 2024 results. This R&D emphasis supports sustained revenue growth, particularly in the US market where oncology drugs like Enhertu and Imfinzi generate significant sales.

The business model relies on strategic partnerships, such as its collaboration with Daiichi Sankyo on Enhertu, which has become a blockbuster in breast and lung cancer treatments. AstraZeneca plc operates globally but derives about 35% of revenue from the US, making it relevant for American investors tracking biopharma trends.

Main revenue and product drivers for AstraZeneca plc

Oncology remains the top revenue driver, accounting for over 40% of total sales in 2024 per the company's annual report released February 2025. Key products include Tagrisso for lung cancer, with global sales surpassing $5 billion, and Imfinzi for bladder and lung cancers. These blockbusters benefit from strong US reimbursement and high demand in precision medicine.

Rare Diseases and BioPharmaceuticals, including Ultomiris and Farxiga, contribute diversified growth. Farxiga, a SGLT2 inhibitor for heart failure and diabetes, saw US sales rise amid expanding indications approved by the FDA.

Industry trends and competitive position

The biopharma sector faces patent cliffs but AstraZeneca plc counters with a deep pipeline in ADCs and cell therapies. Competitors like Pfizer and Merck vie for oncology dominance, yet AstraZeneca's $23 billion revenue in 2024 positions it strongly, with US exposure enhancing appeal to domestic portfolios.

Why AstraZeneca plc matters for US investors

AstraZeneca plc trades on Nasdaq under AZN, providing direct access for US investors. Its portfolio addresses key US health challenges like cancer and cardio-renal diseases, with 35% revenue from North America. Nasdaq listing ensures liquidity and transparency via SEC filings.

Conclusion

AstraZeneca plc stands as a resilient biopharma leader with a focus on high-unmet-need areas. Its diversified portfolio and global reach, including substantial US operations, support ongoing relevance. Investors monitor pipeline progress and market dynamics for future developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.